GENE ONLINE|News &
Opinion
Blog

Psilocybin
Psychedelics Are Driving a Mental Health Revolution with Long-Lasting Therapeutic Potential
2025-06-17
Easing the Mental Health Burden: How MDMA, Psilocybin, and Other Psychedelics May Open Doors for Treating PTSD, Addiction, and Autism
2025-01-28
Cybin’s Breakthrough: Psychedelic Depression Drug CYB003 Sustains 12-Month Symptom Remission in Major Depressive Disorder
2024-11-19
Shifting From Counterculture to Clinical Applications, The Problems Psychedelics Face Getting to Market
2022-07-22
From Forbidden Drugs to Psychotropic Cures: A “Psychedelic Boom” Breaks New Ground in Treating Mental Illnesses
2022-03-08
Psychedelics Player Goes Public via SPAC
2022-01-25
Magic Mushrooms Have the Potential as Depression Therapy?Compass Pathways Filing for IPO
2020-09-20
LATEST
Lupin Secures US FDA Tentative Approval for Oxcarbazepine ER Tablets Manufactured in Nagpur
2025-06-18
Investor Trust and Market Timing Shape the New IPO Playbook
2025-06-18
Global Pharmaceutical Sector Records $6.96 Billion in May 2025 Deal Activity with Three Major Agreements Driving 59 Percent of M&A Value
2025-06-18
Eli Lilly Acquires SiteOne Therapeutics to Develop Non-Opioid Pain Treatment STC-004
2025-06-18
New Device Promises to Streamline CAR T-Cell Therapy Production for Earlier Cancer Treatment
2025-06-18
Roche Reports Near-Complete Suppression of Disability Progression in RMS Patients Over Two Years with BTK Inhibitor
2025-06-18
Technological Advancements Reduce R&D Costs and Propel Growth of Cell and Gene Therapies in Biopharmaceutical Sector
2025-06-18
EVENT
2025-06-16
US BIO International Convention
Boston, U.S.A.
Scroll to Top